Q-omics provides the consensus-scored RIN3 profile across patient tissues and cancer cell-line models. RIN3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RIN3 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RIN3 protein abundance shows 29,221 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRC, and LSCC as cancer lineages where RIN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RIN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RIN3 survival associations across molecular data types. RIN3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RIN3 RNA expression–survival associations across cancer types. High RIN3 expression shows unfavorable associations in LUAD and LUSC, but favorable associations in ACC, PAAD, THYM and CHOL. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RIN3 RNA expression.
This table summarizes RIN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RIN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RIN3 shows lower tumor expression in LUAD, LUSC and UCEC and higher tumor expression in KIRC, HNSC and THCA. The KIRC box plot shows higher RIN3 RNA expression in tumor versus normal tissue (log2 FC = +1.545, t-test p < 0.001).
This table shows molecular features associated with RIN3 in patient tissues and cancer cell lines. In patient samples, RIN3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RIN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BONE.
